ERBB2 and breast carcinoma: Collectively, these results indicate that the efficacy of immunotherapy in metastatic breast cancer outside of the TNBC setting is in the very early stages of investigation, and much work is needed to establish whether there is a role for these agents for HER2+ and ER+ disease.